Stock News

Kerrisdale Advisers Has Lowered Holding in Adamas Pharmaceuticals (ADMS) as Share Price Declined; Monsanto Co New (MON) Shareholder Yhb Investment Advisors Has Decreased Stake by $2.84 Million as Shares Rose

Monsanto Company (NYSE:MON) Logo

Sahm Adrangi decreased its stake in Adamas Pharmaceuticals Inc (ADMS) by 89.36% based on its latest 2017Q4 regulatory filing with the SEC. Kerrisdale Advisers Llc sold 682,642 shares as the company’s stock declined 31.02% with the market. The hedge fund run by Sahm Adrangi held 81,285 shares of the health care company at the end of 2017Q4, valued at $2.76 million, down from 763,927 at the end of the previous reported quarter. Kerrisdale Advisers Llc who had been investing in Adamas Pharmaceuticals Inc for a number of months, seems to be less bullish one the $753.01M market cap company. The stock increased 1.52% or $0.42 during the last trading session, reaching $28.09. About 877,843 shares traded. Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has risen 35.83% since April 21, 2017 and is uptrending. It has outperformed by 24.28% the S&P500.

Yhb Investment Advisors Inc decreased its stake in Monsanto Co New (MON) by 41.18% based on its latest 2017Q4 regulatory filing with the SEC. Yhb Investment Advisors Inc sold 24,508 shares as the company’s stock rose 1.12% while stock markets declined. The institutional investor held 35,000 shares of the agricultural chemicals company at the end of 2017Q4, valued at $4.09 million, down from 59,508 at the end of the previous reported quarter. Yhb Investment Advisors Inc who had been investing in Monsanto Co New for a number of months, seems to be less bullish one the $55.16 billion market cap company. The stock increased 0.32% or $0.4 during the last trading session, reaching $125. About 3.71M shares traded. Monsanto Company (NYSE:MON) has risen 3.06% since April 21, 2017 and is uptrending. It has underperformed by 8.49% the S&P500.

Investors sentiment decreased to 0.81 in Q4 2017. Its down 0.03, from 0.84 in 2017Q3. It dropped, as 69 investors sold MON shares while 328 reduced holdings. 75 funds opened positions while 246 raised stakes. 317.44 million shares or 1.24% less from 321.42 million shares in 2017Q3 were reported. Addenda Cap Inc has invested 0.44% in Monsanto Company (NYSE:MON). Riverpark Limited Liability Com invested 0.19% of its portfolio in Monsanto Company (NYSE:MON). Regentatlantic Limited Liability holds 0.02% or 1,950 shares. Kentucky Retirement Fund has invested 0.23% in Monsanto Company (NYSE:MON). Cobblestone Advsr Ltd Company Ny invested in 2,129 shares. 114 are held by Willingdon Wealth. Livforsakringsbolaget Skandia Omsesidigt reported 6,639 shares. Private Tru Na invested in 2,600 shares. Northern invested in 7.32M shares. Natl Bank Of America De reported 4.17 million shares or 0.08% of all its holdings. Integral Derivatives Ltd Liability has 0.02% invested in Monsanto Company (NYSE:MON) for 8,810 shares. Geode Management reported 4.84M shares. Exxonmobil Invest Tx reported 0.22% stake. Neuberger Berman Grp Incorporated Limited Com reported 569,050 shares. Dowling Yahnke Lc, a California-based fund reported 4,874 shares.

Analysts await Monsanto Company (NYSE:MON) to report earnings on June, 27. They expect $2.19 EPS, up 13.47% or $0.26 from last year’s $1.93 per share. MON’s profit will be $966.42M for 14.27 P/E if the $2.19 EPS becomes a reality. After $3.22 actual EPS reported by Monsanto Company for the previous quarter, Wall Street now forecasts -31.99% negative EPS growth.

Among 23 analysts covering Monsanto Company (NYSE:MON), 10 have Buy rating, 1 Sell and 12 Hold. Therefore 43% are positive. Monsanto Company had 63 analyst reports since August 25, 2015 according to SRatingsIntel. On Monday, April 11 the stock rating was maintained by Goldman Sachs with “Sell”. The stock has “Hold” rating by RBC Capital Markets on Monday, October 9. The firm has “Sector Perform” rating given on Thursday, June 29 by RBC Capital Markets. The stock of Monsanto Company (NYSE:MON) has “Hold” rating given on Thursday, June 29 by Barclays Capital. Barclays Capital maintained it with “Equal Weight” rating and $100.0 target in Thursday, January 7 report. The firm has “Buy” rating given on Friday, September 1 by BMO Capital Markets. As per Tuesday, September 5, the company rating was maintained by RBC Capital Markets. The rating was reinitiated by Morgan Stanley with “Overweight” on Thursday, August 27. The firm earned “Sell” rating on Monday, April 16 by Argus Research. Bernstein upgraded the shares of MON in report on Monday, September 26 to “Mkt Perform” rating.

Since January 9, 2018, it had 0 insider purchases, and 1 insider sale for $966,720 activity.

Monsanto Company (NYSE:MON) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *